Hepatitis B in HIV-infected patients

Clinics in Liver Disease

Volumn 17, Issue 3, 2013, Pages 489-501

  Soriano, Vincent ^a   Poveda, Eva ^a   Vispo, Eugenia ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug resistance; HBV vaccine; HBV HIV coinfection; Hepatocellular carcinoma; Lamivudine; Liver fibrosis; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

CANCER SCREENING; CHILDHOOD; CROSS RESISTANCE; DISEASE TRANSMISSION; ECHOGRAPHY; END STAGE LIVER DISEASE; FULMINANT HEPATIC FAILURE; GENOTYPE; HEPATITIS B; HETEROSEXUALITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PERINATAL PERIOD; REVIEW; SEROCONVERSION; VACCINATION; VIRUS REACTIVATION;

EID: 84881022544     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.05.008     Document Type: Review

References (85)

1. Te H., Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14:1-21.
2. Konopnicki D., Mocroft A., de Wit S., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:2117-2125.
3. Kellerman S., Hanson D., McNaghten A., et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected participants. JInfect Dis 2003, 188:571-577.
4. Modi A., Feld J. Viral hepatitis and HIV in Africa. AIDS Rev 2007, 9:25-39.
5. Chun H., Fieberg A., Hullsied K., et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010, 50:426-436.
6. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. JViral Hepat 2004, 11:97-107.
7. Soriano V., Mocroft A., Peters L., et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. JAntimicrob Chemother 2010, 65:548-555.
8. Wong V., Sung J. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis 2012, 25:570-577.
9. Yeo W., Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
10. McMahon B., Holck P., Bulkow L., et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759-768.
11. Chan H., Leung N., Hussain M., et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000, 31:763-768.
12. Grandjacques C., Pradat P., Stuyver L., et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. JHepatol 2000, 33:430-439.
13. McMahon B. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(Suppl):45-55.
14. Iloeje U., Yang H., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B virus viral load. Gastroenterology 2006, 130:678-686.
15. Chen C., Yang H., Su J., et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
16. Puoti C., Torti C., Bruno R., et al. Natural history of chronic hepatitis B in co-infected patients. JHepatol 2006, 44:S65-S70.
17. Walter S., Thein H., Amin J., et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. JHepatol 2011, 54:879-886.
18. Martín-Carbonero L., Teixeira T., Poveda E., et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011, 25:73-79.
19. Clifford G., Rickenbach M., Polesel J., et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22:2135-2141.
20. Thio C. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49(Suppl):138-145.
21. Weber R., Sabin C., Friis-Moller N., et al. Liver-related deaths in persons with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
22. Nikolopoulos G., Paraskevis D., Hatzitheodorou E., et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009, 48:1763-1771.
23. Thio C., Seaberg E., Skolasky R., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
24. Hoffmann C., Seaberg E., Young S., et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009, 23:1881-1889.
25. DHHS. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf.
26. Thompson M., Aberg J., Hoy J., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
27. European AIDS Clinical Society Guidelines. Version 6.0. October 2011. Available at: http://www.europeanaidsclinicalsociety.org.
28. Soriano V., Tuma P., Vispo E., et al. Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. JHIV Ther 2009, 14(1):13-18.
29. Sulkowski M., Thomas D., Chaisson R., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
30. Aceti A., Pasquazzi C., Zechini B., et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. JAcquir Immune Defic Syndr 2002, 29:41-48.
31. Soriano V., Puoti M., Garcia-Gascó P., et al. Antiretroviral drugs and liver injury. AIDS 2008, 22:1-13.
32. Soriano V., Puoti M., Peters M., et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS 2008, 22:1399-1410.
33. Lok A., McMahon B. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-696.
34. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. JHepatol 2009, 50:227-242.
35. Soriano V., Sheldon J., Ramos B., et al. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS 2006, 20:451-453.
36. McMahon M., Jilek B., Brennan T., et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. NEngl J Med 2007, 356:2614-2621.
37. Soriano V., Perelson A., Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. JAntimicrob Chemother 2008, 62:1-4.
38. Known H., Lock M. Hepatitis B therapy. Gastroenterol Hepatol 2011, 8:275-284.
39. Karatayli E., Karayalcin S., Karaaslan H., et al. Anovel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007, 12:761-768.
40. Tenney D. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 2010, 15:529-535.
41. Sheldon J., Camino N., Rodes B., et al. Selection of hepatitis B virus polymerase mutations in HIV coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727-734.
42. Benhamou Y., Bochet M., Thibault V., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV-infected patients. Hepatology 1999, 30:1302-1306.
43. Hoffmann C., Charalambous S., Martin D., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47:1479-1485.
44. Soriano V., Rivas P., Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 2008, 47:1486-1489.
45. Matthews G., Bartholomeusz A., Locarnini S. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006, 20:863-870.
46. Gouskos T., Wightman F., Chang J., et al. Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus co-infected patient. AIDS 2004, 18:1734-1737.
47. Hsu C., Yeh C., Chang M., et al. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007, 132:543-550.
48. Sheldon J., Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. JAntimicrob Chemother 2008, 61:766-768.
49. Martín-Carbonero L., Soriano V. New paradigms for treating hepatitis B in HIV/HBV co-infected patients. JAntimicrob Chemother 2010, 65:379-382.
50. Thibault V., Aubron-Olivier C., Agut H., et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002, 16:131-133.
51. Tuma P., Pineda J., Labarga P., et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther 2011, 16:585-589.
52. Fujisaki S., Yokomaku Y., Shiino T., et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. JClin Microbiol 2011, 49:1017-1024.
53. Xu Z., Liu Y., Xu T., et al. Acute hepatitis B infection associated with drug resistant hepatitis B virus. JClin Virol 2010, 48:270-274.
54. Fung S, Mazulli T, El-Kashab M, etal. Lamivudine-resistant mutation among treatment-naïve hepatitis B patients is common and may be associated with treatment failure. American Association for the Study of Liver Diseases. 31 Oct-4 Nov 2008; San Francisco, CA, USA [Abstract 888].
55. Soriano V, McMahon B. Rethinking therapeutic strategies for hepatitis B. J Antimicrob Chemother, in press.
56. Lok A., Lai C., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
57. Labarga P., Barreiro P., Martin-Carbonero L., et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009, 23:689-696.
58. Del Palacio M., Romero S., Casado J.L. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012, 14:179-187.
59. Rifkin B., Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004, 117:282-284.
60. Karras A., Lafaurie M., Furco A., et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003, 36:1070-1073.
61. Bedimo R., Maalouf N., Zhang S., et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012, 26:825-831.
62. Chen L., Zhang Q., Yu D.M., et al. Early changes of HBV quasispecies during lamivudine treatment and the correlation with antiviral efficacy. JHepatol 2009, 50:895-905.
63. Chang M., Chien R., Yeh C., et al. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. JHepatol 2005, 43:72-77.
64. Koklu S., Tuna Y., Gulsen M., et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013, 11:88-94.
65. Baxa D., Thekdi A., Golembieski A. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol 2013, 58:212-216.
66. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995, 13:S47-S49.
67. Schirmera P., Wintersb M., Holodniy M. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. JClin Virol 2011, 52:261-264.
68. Gandhi R., Wurcel A., Lee H., et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. JInfect Dis 2005, 191:1435-1441.
69. Rivas P., Herrero M.D., Puente S., et al. Immunizations in HIV-infected adults. AIDS Rev 2007, 9:173-187.
70. Launay O., van der Vliet D., Rosenberg A.R., et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011, 305:1432-1440.
71. World Health Organisation Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009, 84:405-419.
72. Wedemeyer H., Heidrich B., Manns M.P. Hepatitis D virus infection-not a vanishing disease in Europe!. Hepatology 2007, 45:1331-1332.
73. Soriano V., Grint D., d'Arminio-Monforte A., et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011, 25:1987-1992.
74. Calle-Serrano B., Manns M.P., Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis 2012, 32:120-129.
75. Kew M. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. JViral Hepat 2013, 20:149-157.
76. Farci P., Niro G. Clinical features of hepatitis D. Semin Liver Dis 2012, 32:228-236.
77. Erhardt A., Gerlich W., Starke C., et al. Treatment of chronic hepatitis D with pegylated interferon-a 2b. Liver Int 2006, 26:805-810.
78. Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis 2012, 32:237-244.
79. Farci P., Roskams T., Chessa L., et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004, 126:1740-1749.
80. Niro G., Ciancio A., Gaeta G., et al. Pegylated interferon alpha 2b as monotherapy or in combination with ribavirin in chronic hepatitis D. Hepatology 2006, 44:713-720.
81. Yurdaydin C., Bozkaya H., Onder F., et al. Treatment of chronic d hepatitis with lamivudine vs lamivudine+ interferon vs interferon. JViral Hepat 2008, 15:314-321.
82. Wedemeyer H., Yurdaydìn C., Dalekos G., HIDIT Study Group, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. NEngl J Med 2011, 364:322-331.
83. Sheldon J., Ramos B., Toro C., et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. Antivir Ther 2008, 13:97-102.
84. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006, 44:536-539.
85. Roche B., Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis 2012, 32:245-255.